# A Compassionate Case Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Glaucoma Patients With Uncontrolled Intraocular Pressure to Avoid Surgical Intervention

> **NCT02174991** · PHASE2 · UNKNOWN · sponsor: **New York Glaucoma Research Institute** · enrollment: 10 (estimated)

## Conditions studied

- Glaucoma

## Interventions

- **DRUG:** Rho-Kinase Inhibitor (AR-12286)

## Key facts

- **NCT ID:** NCT02174991
- **Lead sponsor:** New York Glaucoma Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-06
- **Primary completion:** 2015-02
- **Final completion:** —
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2015-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02174991

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02174991, "A Compassionate Case Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Glaucoma Patients With Uncontrolled Intraocular Pressure to Avoid Surgical Intervention". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02174991. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*